Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q3 2016 · 10-Q
Revenue-$163.00K-$163.00Kno prior Q3 2015 on file Net Income$2.00M$2.00MN/M vs Q3 2015 EPS Diluted$0.15$0.15±0.0% vs Q3 2015 Operating Income$2,110,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,232,000N/M Margins · derivedOperating margin-1294.5%
Net margin-1224.5%
ended May 31, 2016 · filed Jul 6, 2016 · 36 d after period end